These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6722235)

  • 1. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives.
    Mattes JA; Nayak D
    Biol Psychiatry; 1984 Mar; 19(3):445-9. PubMed ID: 6722235
    [No Abstract]   [Full Text] [Related]  

  • 2. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
    Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
    J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of depot neuroleptics: clinical experience in the United States.
    Kane JM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lithium prophylaxis in schizoaffective psychoses].
    Lenz G; Küfferle B; Wolf R
    Bibl Psychiatr; 1981; (161):45-57. PubMed ID: 7023468
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
    Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
    Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depot fluphenazine: risk/benefit ratio.
    Glazer WM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Schizophrenia and treatment with lithium salts. Current data from the literature].
    Matot JP; Olié JP; Lôo H
    Encephale; 1983; 9(1):49-57. PubMed ID: 6872934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of schizophrenic psychoses by sustained-action neuroleptics in psychiatric outpatients' treatment (author's transl)].
    Polácek J
    Cesk Psychiatr; 1982 Feb; 78(1):49-55. PubMed ID: 7060182
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical significance of depot fluphenazine decanoate in therapy of acute psychotic disorders].
    Ngui PW
    Seishin Shinkeigaku Zasshi; 1983; 85(9):635-9. PubMed ID: 6676769
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study.
    Biederman J; Lerner Y; Belmaker RH
    Arch Gen Psychiatry; 1979 Mar; 36(3):327-33. PubMed ID: 369472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic lithium treatment: treatment response, and patient attitudes toward illness and treatment.
    Schmidt S; Ludwig W; Seibold S; Greil W
    Pharmacopsychiatry; 1988 Nov; 21(6):274-5. PubMed ID: 3244750
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjunctive imipramine maintenance treatment in schizophrenic patients with remitted postpsychotic depression.
    Siris SG; Cutler J; Owen K; Mason S; Gingerich S; Lang MP
    Am J Psychiatry; 1989 Nov; 146(11):1495-7. PubMed ID: 2817126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse in patients with shifting RDC diagnoses treated with lithium alone.
    Glazer WM; Sheard MH
    J Clin Psychiatry; 1982 Apr; 43(4):134-6. PubMed ID: 7068543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipramine-responsive panic-like symptomatology in schizophrenia/schizoaffective disorder.
    Siris SG; Aronson A; Sellew AP
    Biol Psychiatry; 1989 Feb; 25(4):485-8. PubMed ID: 2649158
    [No Abstract]   [Full Text] [Related]  

  • 18. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical picture, therapy and rehabilitation of patients with slowly-progressive (psychopath-like) schizophrenia with a loss of work capacity].
    Niss AI; Shibakova TL
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(6):914-8. PubMed ID: 2875583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical experience with depot neuroleptic treatment].
    Waldmann KD; Neumann J
    Z Arztl Fortbild (Jena); 1984; 78(20):853-6. PubMed ID: 6523910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.